Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2015, on Tuesday, March 1, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss 2015 financial results and provide a business update. The Company will also discuss results from Part 1 of an ongoing Phase 1 trial comparing a single-dose tablet formulation of CTP-656 to the commercial tablet formulation of Kalydeco® (ivacaftor). Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International). A live webcast may be accessed in the Investors section of the Company's website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert's website for three months. About Concert Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, genetic diseases, and inflammatory diseases. For more information, please visit www.concertpharma.com. Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc. Kalydeco is a registered trademark of Vertex Pharmaceuticals, Inc.